Analyst Jason Gerberry of Bank of America Securities reiterated a Hold rating on United Therapeutics, retaining the price target of $463.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry’s rating is based on the analysis of recent data from United Therapeutics’ TETON-2 Phase 3 trial for Tyvaso in treating idiopathic pulmonary fibrosis (IPF). The trial results showed consistent efficacy across various patient sub-groups, with a notable placebo-adjusted reduction in forced vital capacity decline. However, the differences in treatment effects compared to competitors like Boehringer Ingelheim’s nerandomilast were not substantial enough to establish Tyvaso as superior, given the cross-study variations.
Moreover, while the safety profile of Tyvaso was generally comparable to placebo, there was a higher rate of study discontinuation due to adverse events, which was attributed to the demands of nebulizer use. This factor, along with the anticipation of further data from the TETON-1 trial, led to maintaining a Hold rating. The current evidence suggests a positive outlook for Tyvaso, but the competitive landscape and pending trial results warrant a cautious approach.
Based on the recent corporate insider activity of 162 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.